Cellectis S.a. share price today

(CLLS)

Cellectis S.a. share price is $1.64 & ₹139.36 as on 21 Dec 2024, 2.30 'hrs' IST

$1.64

▲

0.05

(3.14%)

Market is closed - opens 8 PM, 23 Dec 2024

View live Cellectis S.a. share price in Dollar and Rupees. Guide to invest in Cellectis S.a. from India. Also see the sentimental analysis on Indian investors investing in Cellectis S.a.. Get details on the Indian mutual funds that are investing in Cellectis S.a.. Get Analyst recommendations and forecasts along with all the Cellectis S.a.'s financials.

Cellectis S.a. share price movements

Today's Low: $1.53
Today's High: $1.64
$1.64
6.71%
Downside
Day's Volatility :6.71%
Upside
0.0%
52 Weeks Low: $1.53
52 Weeks High: $3.55
$1.64
6.71%
Downside
52 Weeks Volatility :56.9%
Upside
53.8%

Cellectis S.a. Returns

Period	Cellectis S.a.	Sector (Health Care)	Index (Russel 2000)
3 Months	-25.45%	-11.1%	0.0%
6 Months	-14.14%	-6.0%	0.0%
1 Year	-53.01%	2.7%	0.0%
3 Years	-80.41%	0.6%	-19.7%

Cellectis S.a. Key Statistics

in dollars & INR

Previous Close	$1.59
Open	$1.58
Today's High	$1.64
Today's Low	$1.53
Market Capitalization	$163.5M
Today's Volume	$87.9K
52 Week High	$3.55
52 Week Low	$1.53
Revenue TTM	$36.0M
EBITDA	$-67.2M
Earnings Per Share (EPS)	$-1.16
Profit Margin	-234.39%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-82.2%

How to invest in Cellectis S.a. from India?

It is very easy for Indian residents to invest directly in Cellectis S.a. from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Cellectis S.a. stock in both Indian Rupees (INR) and US Dollars (USD). Search for Cellectis S.a. or CLLS on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Cellectis S.a. or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Cellectis S.a. shares which would translate to 0.518 fractional shares of Cellectis S.a. as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Cellectis S.a., in just a few clicks!

Returns in Cellectis S.a. for Indian investors in Rupees

Investment Value

₹1,00,000

Cellectis S.a. investment value today

Current value as on today

₹1,55,205

Returns

₹55,205

(+55.2%)

Returns from Cellectis S.a. Stock

₹53,009 (false-53.01%)

Dollar Returns

₹2,196 (+2.2%)

Indian investors sentiment towards Cellectis S.a.

-27%

Period: Sep 21, 2024 to Dec 20, 2024. Change in 30 Days versus previous period

Search volume for Cellectis S.a. on INDmoney from India has reduced in the last 30 days as on Dec 21, 2024. -27% less investors are searching Cellectis S.a. in the last 30 days versus the previous period.

Global Institutional Holdings in Cellectis S.a.

Long Focus Capital Management, LLC
4.61%
Capital Research & Mgmt Co - Division 3
1.85%
UBS Asset Mgmt Americas Inc
1.44%
Baillie Gifford & Co Limited.
0.69%
Principal Financial Group Inc
0.41%
Macquarie Group Ltd
0.23%

Analyst Recommendation on Cellectis S.a.

Buy

85%Buy

14%Hold

0%Sell

Based on 14 Wall street analysts offering stock ratings for Cellectis S.a.(by analysts ranked 0 to 5 stars)

Based on 14 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Cellectis S.a.

What analysts predicted

Upside of 306.51%

Current:

$1.64

Target:

$6.67

Insights on Cellectis S.a.

Price Movement
In the last 3 months, CLLS stock has moved down by -27.3%
Increasing Revenue
Revenue is up for the last 7 quarters, 139.0K → 16.2M (in $), with an average increase of 40.6% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -25.27M → -23.05M (in $), with an average increase of 9.6% per quarter
CLLS vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 35.5% return, outperforming this stock by 86.8%
CLLS vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 23.0% return, outperforming this stock by 103.5%
Price to Sales
ForCLLS every $1 of sales, investors are willing to pay $3.7, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.9 for every $1 of sales.

Cellectis S.a. Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$12.7M	↓ 49.46%
Net Income	$-78.7M	↓ 20.81%
Net Profit Margin	-618.12%	↓ 223.61%

	FY19	Y/Y Change
Revenue	$15.2M	↑ 19.32%
Net Income	$-90.7M	↑ 15.24%
Net Profit Margin	-597.01%	↑ 21.11%

	FY20	Y/Y Change
Revenue	$73.9M	↑ 386.83%
Net Income	$-72.6M	↓ 19.98%
Net Profit Margin	-98.14%	↑ 498.87%

	FY21	Y/Y Change
Revenue	$73.9M	↑ 0.0%
Net Income	$-86.3M	↑ 18.89%
Net Profit Margin	-116.68%	↓ 18.54%

	FY22	Y/Y Change
Revenue	$19.2M	↓ 74.08%
Net Income	$-98.7M	↑ 14.38%
Net Profit Margin	-514.78%	↓ 398.1%

	FY23	Y/Y Change
Revenue	$755.0K	↓ 96.06%
Net Income	$-101.1M	↑ 2.4%
Net Profit Margin	-13.4K%	↓ 12870.52%

	Q2 FY23	Q/Q Change
Revenue	$155.0K	↑ 11.51%
Net Income	$-17.5M	↓ 41.87%
Net Profit Margin	-11.3K%	↑ 10357.26%

	Q3 FY23	Q/Q Change
Revenue	$283.0K	↑ 82.58%
Net Income	$-42.9M	↑ 145.18%
Net Profit Margin	-15.1K%	↓ 3866.87%

	Q4 FY23	Q/Q Change
Revenue	$283.0K	↑ 0.0%
Net Income	$-42.9M	↑ 0.0%
Net Profit Margin	-15.1K%	↑ 0.0%

	Q1 FY24	Q/Q Change
Revenue	$4.5M	↑ 1500.0%
Net Income	$5.6M	↓ 113.17%
Net Profit Margin	124.62%	↑ 15270.2%

	Q2 FY24	Q/Q Change
Revenue	$8.1M	↑ 78.03%
Net Income	$-25.3M	↓ 547.81%
Net Profit Margin	-313.48%	↓ 438.1%

	Q3 FY24	Q/Q Change
Revenue	$16.2M	↑ 100.97%
Net Income	$-23.1M	↓ 8.76%
Net Profit Margin	-142.32%	↑ 171.16%

	FY18	Y/Y Change
Profit	$10.0M	↓ 55.72%

	FY19	Y/Y Change
Profit	$3.8M	↓ 61.99%

	FY20	Y/Y Change
Profit	$37.7M	↑ 891.94%

	FY21	Y/Y Change
Profit	$37.7M	↑ 0.0%

	FY22	Y/Y Change
Profit	$17.4M	↓ 53.82%

	FY23	Y/Y Change
Profit	$18.0K	↓ 99.9%

	Q2 FY23	Q/Q Change
Profit	$-26.0K	↓ 86.67%

	Q3 FY23	Q/Q Change
Profit	$-5.1M	↑ 19361.54%

	Q4 FY23	Q/Q Change
Profit	$116.0K	↓ 102.29%

	Q1 FY24	Q/Q Change
Profit	$-41.0K	↓ 135.34%

	Q2 FY24	Q/Q Change
Profit	$3.3M	↓ 8229.27%

	Q3 FY24	Q/Q Change
Profit	$11.5M	↑ 244.43%

	FY18	Y/Y Change
Operating Cash Flow	$-68.1M	↑ 30.21%
Investing Cash Flow	$35.6M	↑ 1896.8%
Financing Cash Flow	$236.5M	↑ 473.1%

	FY19	Y/Y Change
Operating Cash Flow	$-69.1M	↑ 1.47%
Investing Cash Flow	$-35.9M	↓ 200.7%
Financing Cash Flow	$-3.9M	↓ 101.63%

	FY20	Y/Y Change
Operating Cash Flow	$-80.3M	↑ 16.08%
Investing Cash Flow	$-54.3M	↑ 51.49%
Financing Cash Flow	$27.3M	↓ 807.46%

	FY21	Y/Y Change
Operating Cash Flow	$-104.6M	↑ 30.28%
Investing Cash Flow	$7.3M	↓ 113.39%
Financing Cash Flow	$47.5M	↑ 73.94%

	FY22	Y/Y Change
Operating Cash Flow	$-87.4M	↓ 16.37%
Investing Cash Flow	$-2.8M	↓ 137.93%
Financing Cash Flow	$1.1M	↓ 97.59%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-17.1M	↓ 39.65%
Investing Cash Flow	$-1.8M	↑ 0.0%
Financing Cash Flow	$1.7M	↓ 91.47%

Cellectis S.a. Technicals Summary

Sell

Neutral

Buy

Cellectis S.a. is currently in a neutral trading position according to technical analysis indicators.

Cellectis S.a. Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Cellectis S.a.	-11.83%	-14.14%	-53.01%	-80.41%	-91.31%
Regeneron Pharmaceuticals, Inc.	-5.73%	-34.03%	-17.11%	13.66%	87.56%
Biontech Se	4.48%	30.56%	7.36%	-56.46%	225.6%
Alnylam Pharmaceuticals, Inc.	-0.55%	10.11%	28.49%	30.99%	109.19%
Vertex Pharmaceuticals Incorporated	-11.79%	-16.36%	-1.97%	78.33%	80.59%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Cellectis S.a.	NA	NA	0.0	-0.7	-0.82	-0.16	NA	1.29
Regeneron Pharmaceuticals, Inc.	17.51	17.51	1.06	45.07	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.11	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.17	0.55	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Cellectis S.a.	Buy	$163.5M	-91.31%	NA	-234.39%
Regeneron Pharmaceuticals, Inc.	Buy	$77.8B	87.56%	17.51	33.61%
Biontech Se	Buy	$26.7B	225.6%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$30.8B	109.19%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$102.1B	80.59%	32.84	-4.51%

About Cellectis S.a.

cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.

Organization	Cellectis S.a.
Employees	216
CEO	Dr. Andre Choulika Ph.D.
Industry	Health Technology

Management People of Cellectis S.a.

Name	Title
Dr. Andre Choulika Ph.D.	Co-Founder, CEO & Director
Dr. David j. d. Sourdive Ph.D.	Deputy CEO, Executive VP of CMC & Manufacturing and Director
Mr. Arthur Stril	Interim Chief Financial Officer
Valerie Cros	Principal Financial Officer & Principal Accounting Officer
Mr. Jean Charles Epinat	Chief Technological Officer
Dr. Philippe Duchateau Ph.D.	Chief Scientific Officer
Ms. Marie-Bleuenn Terrier	General Counsel & Secretary of the Board of Directors
Pascalyne Wilson	Director of Communications
Ms. Kyung Nam-Wortman	Executive VP & Chief Human Resources Officer
Mr. Stephan Reynier M.Sc.	Chief Regulatory & Pharmaceutical Compliance Officer

Important FAQs about investing in Cellectis S.a. from India :

What is Cellectis S.a. share price today?

Cellectis S.a. share price today stands at $1.64, Open: $1.58 ; Previous Close: $1.59 ; High: $1.64 ; Low: $1.53 ; 52 Week High: $3.55 ; 52 Week Low: $1.53. The stock opens at $1.58, after a previous close of $1.59. The stock reached a daily high of $1.64 and a low of $1.53, with a 52-week high of $3.55 and a 52-week low of $1.53.

Can Indians buy Cellectis S.a. shares?

Yes, Indians can invest in the Cellectis S.a. (CLLS) from India.

With INDmoney, you can buy Cellectis S.a. at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Cellectis S.a. at zero transaction cost.

How can I buy Cellectis S.a. shares from India?

It is very easy to buy Cellectis S.a. from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Cellectis S.a. be purchased?

Yes, you can buy fractional shares of Cellectis S.a. with INDmoney app.

What are the documents required to start investing in Cellectis S.a. stocks?

To start investing in Cellectis S.a., You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.